Pilot study for the characterization of pharmacogenetically relevant CYP2D6, CYP2C19 and ABCB1 gene polymorphisms in the Hungarian population

Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON–TIMI 38 trial: a pharmacogenetic analysis

(2010) Jessica L Mega et al.   LANCET

Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial

(2010) Lars Wallentin et al.   LANCET

Characterization of pharmacogenetically relevantCYP2D6andABCB1gene polymorphisms in a Portuguese population sample

(2009) C. Correia et al.   CELL BIOCHEMISTRY AND FUNCTION

Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales

(2009) Johanna Sistonen et al.   Pharmacogenetics and Genomics

Effect of CYP2C19 *2 and *17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians

(2008) Nicole G. Hunfeld et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Genetic Determinants of Response to Clopidogrel and Cardiovascular Events

(2008) Tabassome Simon et al.   NEW ENGLAND JOURNAL OF MEDICINE

The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction

(2008) M C Rebsamen et al.   PHARMACOGENOMICS JOURNAL